Investigating the efficacy of oral propranolol in prevention of severe Retinopathy of Prematurity

Investigating the efficacy of oral propranolol in prevention of severe Retinopathy of Prematurity : A Randomized Clinical Trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20101018004961N12

Enrollment

Registered

2021-07-17

Start date

2021-07-04

Completion date

Unknown

Last updated

2021-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Retinopathy of prematurity. Retinopathy of prematurity

Interventions

Intervention group: In the study group, after diagnosis of grade 1 or 2 retinopathy of prematurity in ophtalmic examination, oral propranolol (Hakim Pharmaceutical Company - Made in Iran) is started

Eligibility

Sex/Gender

All

Age

28 Days to 120 Days

Inclusion criteria

Inclusion criteria: newborns with gestational age =34 weeks or birth weight =2000?g with retinopathy of prematurity stage I or II

Exclusion criteria

Exclusion criteria: Infants with congenital anomalies heart diseases except PDA recurrent bradycardia eye malformations acute renal failure IVH grade II and III, acute sepsis

Design outcomes

Primary

Measure	Time frame
Stage of retinopathy. Timepoint: Day 28 after birth and then every 1 to 2 weeks until the retinal vascular are complete. Method of measurement: Ophthalmoscopic eye examination.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactPourang Mohammadi

Kermanshah University of Medical Sciences

pourangmohammadi@yahoo.com0098 83 34276300-20

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026